Coronary disease & ACSTrial design
Stratified medicine with eplerenone for myocardial infarction or injury and no obstructive coronary arteries: A registry-based basket trial
- prospective, registry-based, multicenter, diagnostic study and nested, randomized, controlled, open-label, blinded-endpoint (PROBE) basket trial
- endotypes centrally adjudicated by a panel of blinded cardiologists
- intention-to-treat
Study context
- Population
- Patients with clinically suspected Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) and one or more cardiovascular risk factors; patients with an index of coronary microvascular resistance (IMR) ≥ 25 randomizedplanned enrolment into the registry-based diagnostic study, n = 150 randomized · randomized (IMR ≥ 25) 150
- Participants
- Up to 400 patients
- Planned comparison
- eplerenone or standard care without eplerenone
- Primary endpoint
- Within-individual change in NT-proBNP (primary outcome of the randomized trial), intention-to-treat
- Follow-up
- Baseline, 1 month, and 6 months
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Proportion of patients with IMR ≥ 25 during index coronary angiography (primary outcome of the diagnostic study)
- protocol; no results reported
Original publication
Stratified medicine with eplerenone for myocardial infarction or injury and no obstructive coronary arteries: A registry-based basket trial. Am Heart J. Published 2 July 2026. doi:10.1016/j.ahj.2026.107518
Summarised from the published abstract; every number is checked against it